Chemo Research, S.l.

Enrico Colli

David F Archer

Salustiano Pérez

The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea, comprising administering drospirenone in a biphasic regimen. The present invention furthermore relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to a pharmaceutical composition and a kit comprising drospirenone administered in such a biphasic regimen.

Method for treating endometriosis and providing effective contraception

The invention relates to a new modified release oral pharmaceutical form comprising 17α-cyanomethyl-17-β-hydrox-yestra-4,9-dien-3-one (dienogest) and 17aα-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.

Modified release oral contraceptive composition

The invention relates to a new modified release oral pharmaceutical form comprising 17α-cyanomethyl-17-ß-hydroxyestra-4,9-dien-3-one (dienogest) and 17α-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.

The invention relates to vaginal composition comprising a combination of estrogen and vitamin D or a vitamin D analog at a daily dosage delivery of (i) estrogen ranging from 1 &#x3bc;g to 100 &#x3bc;g estrogen of estradiol equivalent and (ii) vitamin D or analog ranging from 7.5 &#x3bc;g to 100 &#x3bc;g of vitamin D equivalent.

Growing community of inventors

Madrid, Spain

Enrico Colli